Related references
Note: Only part of the references are listed.Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
Xiuning Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N. Mathieu et al.
CLINICAL CANCER RESEARCH (2022)
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial
Yasir Y. Elamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
David Planchard et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
Xin Yu et al.
FRONTIERS IN ONCOLOGY (2022)
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
Tony S. K. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy
Naoki Haratake et al.
CLINICAL LUNG CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Crizotinib in Patients With MET-Amplified NSCLC
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou et al.
JAMA ONCOLOGY (2021)
First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
Andrea Spini et al.
CANCERS (2021)
OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
K. Nakagawa et al.
Journal of Thoracic Oncology (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion plus NSCLC and RET-mutant MTC: Phase 1 study results.
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor et al.
LANCET ONCOLOGY (2021)
Toward personalized treatment approaches for non-small-cell lung cancer
Meina Wang et al.
NATURE MEDICINE (2021)
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu et al.
LANCET RESPIRATORY MEDICINE (2021)
MET Exnn 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
Mark A. Socinski et al.
JCO PRECISION ONCOLOGY (2021)
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer
Caroline E. McCoach et al.
JCO PRECISION ONCOLOGY (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
NTRK gene fusions: a rough diamond ready to sparkle
Christian Rolfo
LANCET ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Aaron C. Tan et al.
LUNG CANCER (2020)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T. Mok et al.
ANNALS OF ONCOLOGY (2020)
Molecular profiling for precision cancer therapies
Eoghan R. Malone et al.
GENOME MEDICINE (2020)
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer
Till Wallrabenstein et al.
PLOS ONE (2020)
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
Alessandro Russo et al.
CURRENT ONCOLOGY REPORTS (2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
J. J. Lin et al.
ANNALS OF ONCOLOGY (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Aparna Hegde et al.
ESMO OPEN (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations
Vincent K. Lam et al.
CLINICAL LUNG CANCER (2019)
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat et al.
CLINICAL CANCER RESEARCH (2019)
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
W. Victoria Lai et al.
EUROPEAN JOURNAL OF CANCER (2019)
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Helen Adderley et al.
EBIOMEDICINE (2019)
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
V. Gambardella et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
Kiichiro Ninomiya et al.
CHEST (2019)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C. Marchio et al.
ANNALS OF ONCOLOGY (2019)
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi et al.
CLINICAL CANCER RESEARCH (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y. Wang et al.
ANNALS OF ONCOLOGY (2019)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters et al.
CLINICAL CANCER RESEARCH (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
Henning Reis et al.
CLINICAL LUNG CANCER (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
Katsuyuki Hotta et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis
Huy Gia Vuong et al.
LUNG CANCER (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Solange Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications , and Concurrent Alterations
Yuri Sheikine et al.
JCO PRECISION ONCOLOGY (2018)
Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
B. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion
Anna F. Farago et al.
JCO PRECISION ONCOLOGY (2018)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
Geun Dong Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project
Lukas Bubendorf et al.
LUNG CANCER (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting TRK family proteins in cancer
Yekaterina B. Khotskaya et al.
PHARMACOLOGY & THERAPEUTICS (2017)
EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
Amit Joshi et al.
ONCOTARGETS AND THERAPY (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Lung Cancer: Understanding its Molecular Pathology and the 2015 WHO Classification
Kentaro Inamura
FRONTIERS IN ONCOLOGY (2017)
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Rathi N. Pillai et al.
CANCER (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
R32Druggable aberrations in solid tumors: an overview on ALK and ROS-1 status
M.S. Cona et al.
ANNALS OF ONCOLOGY (2016)
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J. Mazieres et al.
ANNALS OF ONCOLOGY (2016)
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
Francesco Passiglia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients
Sebastian Michels et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare
Weijie Zhao et al.
LUNG CANCER (2016)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell et al.
NATURE GENETICS (2016)
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma
Anna Biernacka et al.
CANCER GENETICS (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
M. G. Kris et al.
ANNALS OF ONCOLOGY (2015)
The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis
Chen Lin et al.
CANCER BIOLOGY & THERAPY (2015)
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
Jacques De Greve et al.
LUNG CANCER (2015)
MET Receptor Juxtamembrane Exon 14 Alternative Spliced Variant: Novel Cancer Genomic Predictive Biomarker
Patrick C. Ma
CANCER DISCOVERY (2015)
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
David Casadevall et al.
ONCOTARGET (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations
T. Kinno et al.
ANNALS OF ONCOLOGY (2014)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
K. M. Kerr et al.
ANNALS OF ONCOLOGY (2014)
Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays
Hirotsugu Kenmotsu et al.
BMC CANCER (2014)
NSCLC and HER2 Between Lights and Shadows
Giuseppina Rosaria Rita Ricciardi et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer
Petra Martin et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
Christian Boch et al.
BMJ OPEN (2013)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
Natasha Rekhtman et al.
CLINICAL CANCER RESEARCH (2012)
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer
Rui Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
TrkB inhibition as a therapeutic target for CNS-related disorders
Fabien Boulle et al.
PROGRESS IN NEUROBIOLOGY (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Heounjeong Go et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2009)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
LM Krug et al.
CANCER (2005)
Intragenic ERBB2 kinase mutations in tumours
P Stephens et al.
NATURE (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
P Peschard et al.
MOLECULAR CELL (2001)
Share Paper
